We’re reprinting this interview with Paul Cannon, Ph.D, about treatment for his Parkinson’s as well as updates on 23andMe’s research, that was put together by Tomorrow Edition blogger Benjamin Stecher.
Today, 23andMe is thrilled to announce that we are launching a collaboration with GlaxoSmithKline (GSK) to accelerate our ability to make those novel treatments and cures a reality.
A new Genetic Health Risk Report for G6PD Deficiency looks for one genetic variant linked to episodes of anemia.
Last month 23andMe received the first-ever FDA authorization for a direct-to-consumer genetic health risk test for cancer.
Earlier this month 23andMe added a new Carrier Status* report on a serious but rare condition that can lead to excessive insulin production.
Today, 23andMe received the first-ever FDA authorization for a direct-to-consumer genetic test for cancer risk for its BRCA1/BRCA2 (Selected Variants) report.
Just in time for New Year’s resolutions, 23andMe is embarking on a first-of-its-kind study that will engage with customers to learn more about genetic variants associated with weight loss, and the effectiveness of using different diets or exercise to lose weight.
ZDogg — aka Dr. Zubin Damania, a doctor and a hip-hop humorist of healthcare — was in the house at 23andMe last week, for a conversation with our CEO and co-founder Anne Wojcicki for his Facebook Live show, Incident Report.
This week 23andMe released a new genetic health risk report on celiac disease that looks at two genetic variants — rs2187668 and rs7454108 — that are linked to the HLA-DQ2.5 and HLA-DQ8 haplotypes.
The annual meeting of the American Society of Human Genetics kicks off in Orlando this October packed with five days of seminars, panel discussions, talks, and presentations that are all part of an event that might best be described as the Coachella (or Woodstock if you prefer) of genetics.
